undamentalytics Newsletter
Sign in

Globe Life (GL) stock

Add to watchlist

Add holding +

NYSE: GL NYSE Life & Health Insurance Next results ~February 3, 2027

C+ Fundamentals grade

Globe Life is a US-listed company in the life & health insurance industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 12 selling0 purchases and 81 sales by directors and officers, last 12 monthsInsider trades
  • Funds334 adding, 271 cuttingOf 62 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Globe Life files

Where Globe Life stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $6.19bn, up 5.2% on a year earlier, faster than 4.0% a quarter earlier. The diluted share count is down 5.3% on a year earlier, which lifts each remaining share.

Our model value for Globe Life is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 3, 2027 (estimated)

Globe Life's trailing-twelve-month revenue grew 5.2% year on year, with a free-cash-flow margin of 19.9%. Where it stands out: net margin of 19.6% ranks 4 of 18 life & health insurance companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 8.6% while net income grew 13.8%: a 22pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 5.3% in a year, so each share owns more of the business.

Things to watch

  • Insiders selling. 12 insiders sold $83M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$4.84 against an average estimate of $4.89: missed by 1.1%
Revenue
$1.60bn, up 8.0% on a year earlier
Share reaction
-0.8% in the first session after the results on October 21, 2026, against -0.7% for the S&P 500
Guidance given
earnings guidance $15.35 to $15.65 (full-year 2026); net operating income per share $16.1 to $17.1 (the year ending December 31, 2027)
Next report
October 21, 2026; average EPS estimate $3.61

Globe Life's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.4%
  • 1 week+1.9%
  • 1 month-3.4%
  • This year+15.2%
  • 1 year+22.5%
  • 5 years+80.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$6.2B
Net margin
19.6%
EPS (TTM, diluted)
$15.08

Growth

Revenue growth
+5.2%
Change in growth rate
+1.3 pts
Share count change
−5.3%

Earnings

Last results
October 21, 2026
Next results (est.)
February 3, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Results
  3. Guidance
  4. Insider trade
  5. Leadership
  6. Insider trade
  7. Insider trade
  8. Insider trade
  9. Insider trade
  10. Insider trade
  11. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Globe Life valuation models and calculator

No model value for Globe Life at the moment. Current status: valuation models disagree too widely to rate. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valuation models disagree too widely to rate: held for review.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Globe Life as an insurer, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.89 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$270 ~$190–$390 Primary model, counts double
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$210 ~$180–$250 Included
Price-to-book vs return on equity (peers) The price-to-book that peers with this return on equity trade on, from a line fitted across peers. ~$160 ~$110–$200 Included
Price-to-book vs peers Book value per share times peers' typical (harmonic-mean) price-to-book. ~$0.3 ~$45–$130 Left out: out of range vs price (0.00x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$110 ~$100–$170 Included
Dividend discount (two-stage) Dividends for five years at the growth the business can fund, then a steady payout and growth. ~$210 ~$170–$270 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Globe Life with life and health insurers in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

88 /100

Strong moat

How hard Globe Life's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 3.4% of total assets over 10 years.

  • Durability 16 / 20

    Operating margin has been a median 20.1%; its worst year was 17.4%.

  • Discipline 20 / 20

    The diluted share count fell 23.8% over five years; stock-based pay has been a median 0.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (93 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $15.50 +7% $6.4bn +7%
Next $16.42 +6% $6.8bn +6%

Next year's EPS estimate has moved −0.5% in 90 days, across 11 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.4% on 90 days ago. In the last 30 days, 0 analysts raised Globe Life's forecast and 2 cut it.

Consensus EPS forecast Globe Life, last 90 days
$15.00 $15.50 $16.00 $16.50 $17.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $15.72 Current fiscal year, 60 days ago: $15.73 Current fiscal year, 30 days ago: $15.73 Current fiscal year, 7 days ago: $15.72 Current fiscal year, Now: $15.50 $15.50 Next fiscal year, 90 days ago: $16.50 Next fiscal year, 60 days ago: $16.50 Next fiscal year, 30 days ago: $16.50 Next fiscal year, 7 days ago: $16.51 Next fiscal year, Now: $16.42 $16.42

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $15.72$16.50
60 days ago $15.73$16.50
30 days ago $15.73$16.50
7 days ago $15.72$16.51
Now $15.50$16.42

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $4.89 $4.84 −1.1%
Jun 2026 $3.68 $3.61 −2.0%
Mar 2026 $3.48 $3.43 −1.4%
Dec 2025 $3.44 $3.39 −1.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 21, 2026
  • earnings guidance full-year 2026 $15.35 to $15.65 Lowered vs 15.55 to 15.95
    “The Company adjusted full-year 2026 earnings guidance to a range of $15.35 to $15.65 due to two items impacting the results at our United American General Agency division, rather than a fundamental change in our underlying core business: high-severity claims at Evry, a developing group health business still growing and scaling to a size that will enable stable results, and a claims processing delay at the Centers for Medicare and Medicaid Services which resulted in excess Medicare Supplement claims during the third quarter.” source
  • net operating income per share the year ending December 31, 2027 $16.10 to $17.10 Non-GAAP
    “For the year ending December 31, 2027, we estimate that net operating income per share will be in the range of $16.10 to $17.10, an increase of 7.1% at the midpoint.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

11 analysts, Oct 2026
Buy764%
Hold436%
Sell00%

Monthly trend

  1. Oct 202634411
  2. Sep 202644311
  3. Aug 202644311

Counts of recommendations published by analysts covering Globe Life, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.07
at average volume
Short interest, 1 month
−98%
to October 15, 2026
Held by institutions
87%
of shares
Held by insiders
0.7%
of shares
Employees
3,695
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +22.5%

$130.45 on October 31, 2025 to $159.79

ThenNowEffect
Revenue (last 12 months) $5.9bn $6.2bn +5.2%
Net margin 18.1% 19.6% +8.1%
P/E multiple 10.4x 10.6x +2.0%
Share count 85m 80m +5.6%

Biggest factor: net margin.

Last 3 years +39.9%

$114.18 on November 3, 2023 to $159.79

ThenNowEffect
Revenue (last 12 months) $5.3bn $6.2bn +17.3%
Net margin 16.5% 19.6% +18.6%
P/E multiple 12.8x 10.6x −17.2%
Share count 98m 80m +21.6%

Biggest factor: share count.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GL−1%+30%+2%−8%+27%+15%
Industry peers (median)+20%−4%+20%+28%+9%+11%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GL58%50%50%67%67%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GL−20%−17%−16%−62%−15%−17%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 62% from February 28, 2024 to April 11, 2024. Getting back needed a 161% gain, reached on February 28, 2025, 323 days after the low.

Price behaviour

52-week range
$129.31 – $185.65
From 52-week high
−13.9%
vs 50-day average
−4.8%
vs 200-day average
+0.3%
Volatility (1 year)
21%
Beta vs S&P 500
0.33

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±3.8%
After a week
6 up, 6 down
typical move ±4.9%
After a month
6 up, 5 down
typical move ±6.7%
Results releasedNext dayS&P 500 next day5 days21 days
October 21, 2026 −0.8% −0.7% −6.7% —
July 22, 2026 −7.2% −1.3% −2.5% −7.5%
April 22, 2026 +2.0% +0.6% +1.1% +3.8%
February 4, 2026 +2.3% −1.7% +0.2% −1.0%
October 22, 2025 −0.2% +0.1% −3.1% −4.1%
July 23, 2025 +7.1% +0.9% +14.8% +13.7%
April 30, 2025 −5.0% +0.7% −2.4% −1.7%
February 5, 2025 −2.0% +0.8% −0.8% +2.5%
October 23, 2024 −1.5% −0.7% −3.7% −1.9%
July 24, 2024 −0.5% −2.8% +3.6% +10.5%
April 22, 2024 +13.5% +2.1% +17.0% +24.9%
February 7, 2024 +3.1% +0.9% +3.4% +2.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Globe Life in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Globe Life
$5B $5.5B $6B $6.5B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $5.4B Revenue (TTM), FY23 Q4: $5.4B Revenue (TTM), FY24 Q1: $5.5B Revenue (TTM), FY24 Q2: $5.7B Revenue (TTM), FY24 Q3: $5.7B Revenue (TTM), FY24 Q4: $5.8B Revenue (TTM), FY25 Q1: $5.8B Revenue (TTM), FY25 Q2: $5.9B Revenue (TTM), FY25 Q3: $5.9B Revenue (TTM), FY25 Q4: $6B Revenue (TTM), FY26 Q1: $6.1B Revenue (TTM), FY26 Q2: $6.2B $6.2B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $5.4B
FY23 Q4 $5.4B
FY24 Q1 $5.5B
FY24 Q2 $5.7B
FY24 Q3 $5.7B
FY24 Q4 $5.8B
FY25 Q1 $5.8B
FY25 Q2 $5.9B
FY25 Q3 $5.9B
FY25 Q4 $6B
FY26 Q1 $6.1B
FY26 Q2 $6.2B
Revenue growth, TTM YoY Globe Life
3% 4% 5% 6% 7% 8% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 3.4% Revenue growth, TTM YoY, FY23 Q4: 4.2% Revenue growth, TTM YoY, FY24 Q1: 5.7% Revenue growth, TTM YoY, FY24 Q2: 7.1% Revenue growth, TTM YoY, FY24 Q3: 6.7% Revenue growth, TTM YoY, FY24 Q4: 6.1% Revenue growth, TTM YoY, FY25 Q1: 5.4% Revenue growth, TTM YoY, FY25 Q2: 4.0% Revenue growth, TTM YoY, FY25 Q3: 3.7% Revenue growth, TTM YoY, FY25 Q4: 3.7% Revenue growth, TTM YoY, FY26 Q1: 4.0% Revenue growth, TTM YoY, FY26 Q2: 5.2% 5.2%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 3.4%
FY23 Q4 4.2%
FY24 Q1 5.7%
FY24 Q2 7.1%
FY24 Q3 6.7%
FY24 Q4 6.1%
FY25 Q1 5.4%
FY25 Q2 4.0%
FY25 Q3 3.7%
FY25 Q4 3.7%
FY26 Q1 4.0%
FY26 Q2 5.2%
Operating margin (TTM) Globe Life
22% 24% 26% 28% FY21 Q4 FY22 Q3 FY23 Q2 FY24 Q3 Operating margin (TTM), FY21 Q4: 24.0% Operating margin (TTM), FY22 Q1: 25.9% Operating margin (TTM), FY22 Q2: 27.2% Operating margin (TTM), FY22 Q3: 28.0% Operating margin (TTM), FY22 Q4: 22.7% Operating margin (TTM), FY23 Q1: 22.7% Operating margin (TTM), FY23 Q2: 22.5% Operating margin (TTM), FY23 Q3: 23.2% Operating margin (TTM), FY23 Q4: 23.2% Operating margin (TTM), FY24 Q1: 23.2% Operating margin (TTM), FY24 Q2: 23.3% Operating margin (TTM), FY24 Q3: 24.0% 24.0%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q4 24.0%
FY22 Q1 25.9%
FY22 Q2 27.2%
FY22 Q3 28.0%
FY22 Q4 22.7%
FY23 Q1 22.7%
FY23 Q2 22.5%
FY23 Q3 23.2%
FY23 Q4 23.2%
FY24 Q1 23.2%
FY24 Q2 23.3%
FY24 Q3 24.0%
FCF margin (TTM) Globe Life
18% 20% 22% 24% 26% 28% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 26.4% FCF margin (TTM), FY23 Q4: 26.3% FCF margin (TTM), FY24 Q1: 23.6% FCF margin (TTM), FY24 Q2: 23.9% FCF margin (TTM), FY24 Q3: 24.2% FCF margin (TTM), FY24 Q4: 23.0% FCF margin (TTM), FY25 Q1: 24.1% FCF margin (TTM), FY25 Q2: 22.9% FCF margin (TTM), FY25 Q3: 21.0% FCF margin (TTM), FY25 Q4: 20.9% FCF margin (TTM), FY26 Q1: 20.2% FCF margin (TTM), FY26 Q2: 19.9% 19.9%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 26.4%
FY23 Q4 26.3%
FY24 Q1 23.6%
FY24 Q2 23.9%
FY24 Q3 24.2%
FY24 Q4 23.0%
FY25 Q1 24.1%
FY25 Q2 22.9%
FY25 Q3 21.0%
FY25 Q4 20.9%
FY26 Q1 20.2%
FY26 Q2 19.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 3,115 3,368 3,377 3,590 3,494 3,620 3,766 3,935 4,156 4,304 4,528 4,738 5,112 5,227 5,448 5,778 5,994 6,192
Gross profit 707 713 698 728 747 761 775 783 807 865 911 901 1,215 1,179 1,260 — — —
EBITDA 712 728 739 761 762 779 784 797 832 884 936 922 1,247 1,207 1,286 — — —
Operating income 707 722 732 754 756 772 776 787 821 871 920 905 1,227 1,186 1,265 — — —
Net income 405 499 497 529 528 543 527 550 1,454 701 761 732 1,031 894 971 1,071 1,161 1,212
Diluted EPS $2.17 $2.70 $3.02 $3.60 $3.79 $4.09 $4.16 $4.49 $12.22 $6.09 $6.83 $6.82 $9.99 $9.04 $10.07 $11.94 $14.07 $15.08
Growth (year on year)
Revenue −2.5% +8.1% +0.3% +6.3% −2.7% +3.6% +4.0% +4.5% +5.6% +3.6% +5.2% +4.6% +7.9% +2.2% +4.2% +6.1% +3.7% +5.2%
EBITDA — +2.4% +1.4% +3.0% +0.2% +2.2% +0.7% +1.6% +4.4% +6.2% +5.9% −1.5% +35.2% −3.2% +6.5% — — —
Operating income — +2.2% +1.3% +2.9% +0.3% +2.1% +0.6% +1.4% +4.3% +6.0% +5.7% −1.6% +35.5% −3.3% +6.6% — — —
Net income −10.5% +23.2% −0.3% +6.5% −0.2% +2.7% −2.9% +4.3% +164.6% −51.8% +8.5% −3.8% +40.9% −13.3% +8.5% +10.3% +8.4% +13.8%
Diluted EPS −57.6% +24.6% +11.9% +19.2% +5.3% +7.9% +1.7% +7.9% +172.2% −50.2% +12.2% −0.1% +46.5% −9.5% +11.4% +18.6% +17.8% +20.1%
Margins
Gross margin 22.7% 21.2% 20.7% 20.3% 21.4% 21.0% 20.6% 19.9% 19.4% 20.1% 20.1% 19.0% 23.8% 22.6% 23.1% — — —
EBITDA margin 22.8% 21.6% 21.9% 21.2% 21.8% 21.5% 20.8% 20.3% 20.0% 20.5% 20.7% 19.5% 24.4% 23.1% 23.6% — — —
Operating margin 22.7% 21.5% 21.7% 21.0% 21.6% 21.3% 20.6% 20.0% 19.8% 20.2% 20.3% 19.1% 24.0% 22.7% 23.2% — — —
Net margin 13.0% 14.8% 14.7% 14.7% 15.1% 15.0% 14.0% 14.0% 35.0% 16.3% 16.8% 15.4% 20.2% 17.1% 17.8% 18.5% 19.4% 19.6%
Free-cash-flow margin 31.1% 30.3% 25.3% 26.1% 31.7% 23.4% 28.8% 34.9% 33.9% 28.6% 29.2% 30.3% 27.4% 26.7% 26.3% 23.0% 20.9% 19.9%
Cash flow
Cash from operations 976 1,029 859 943 1,119 865 1,120 1,399 1,429 1,278 1,364 1,476 1,438 1,422 1,482 1,402 1,396 1,392
Capital spending 6 9 5 5 11 19 37 25 20 45 42 42 38 28 50 71 142 159
Free cash flow 970 1,019 854 938 1,108 845 1,083 1,374 1,409 1,233 1,322 1,435 1,399 1,394 1,433 1,331 1,254 1,232
Stock-based pay 10 12 15 22 26 32 29 26 37 40 45 36 30 36 31 40 53 58
Free cash flow after stock pay 960 1,008 839 917 1,082 813 1,054 1,347 1,372 1,193 1,277 1,399 1,369 1,359 1,402 1,291 1,201 1,175
Balance sheet
Cash 232 366 84 62 — — — 76 119 121 76 95 92 93 103 165 145 257
Total debt 1,029 1,112 1,139 1,403 1,220 1,231 1,234 1,400 1,465 1,672 1,657 1,923 2,176 2,243 2,116 2,740 2,625 2,943
Net debt (negative = net cash) 797 747 1,055 1,341 — — — 1,323 1,346 1,551 1,581 1,828 2,084 2,150 2,013 2,574 2,481 2,686
Diluted shares 187m 185m 165m 147m 140m 133m 127m 122m 119m 115m 111m 107m 103m 99m 96m 90m 83m 80m
Returned to shareholders
Dividends 47 50 49 56 61 65 67 67 69 71 74 78 80 81 84 85 86 91
Buybacks 48 246 973 570 482 449 419 405 413 422 460 444 541 455 511 1,002 881 881
Total returned 94 296 1,022 626 543 514 485 472 482 493 534 522 621 535 595 1,088 967 972

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$881M
Dividends (TTM)
$90.6M
Returned to shareholders
79%
of free cash flow
Buybacks, last 3 fiscal years
$2.4B
Diluted share count
−5.3%
year over year
Total shareholder yield
6.6%
dividends 0.6% + buybacks 6.0% of market value
Dividend payout ratio
8%
of net income paid out

Competitors: side by side with peers

Closest by revenue in life & health insurance
Last 12 months unless stated GL FG JXN MFC BHF GNW Median
Revenue, last 12 months $6.2bn $6.1bn $6.5bn $5.8bn $6.7bn $7.4bn $11.1bn
Revenue growth, last 12 months 5.2% 15.0% 15.1% 5.0% 2.6% 2.1% 6.1%
Revenue growth, 3-year average 5.5% 19.4% 43.4% — 37.8% −0.3% 4.9%
Revenue growth, latest quarter 8.0% 4.2% −22.6% — 86.2% 5.8% 6.9%
Operating margin 24.0% — — — — 0.4% 12.3%
Operating margin, 3-year average 25.1% — — — — 4.2% 15.0%
Net margin 19.6% 6.9% 1.6% 68.5% 12.5% 2.9% 6.5%
Cash from operations / revenue 22.5% 71.5% 90.9% 394.9% −8.1% 5.8% 14.6%
Free-cash-flow margin 19.9% 59.9% 90.9% 390.5% — 2.8% 19.4%
Free-cash-flow margin, 3-year average 22.2% 86.7% 106.8% 152.8% — 0.7% 21.3%
Stock pay / revenue 0.9% 0.6% 1.6% 0.0% — 0.9% 0.8%
Change in share count −5.3% 2.7% −5.8% −4.3% −2.6% −6.5% −4.7%

Median of all 18 companies we cover in life & health insurance. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

18 life & health insurance companies
Measure Company Peer median Rank
Revenue growth Growth 5.2% 7.0% 10 of 18
Change in growth rate Growth +1.3pp +1.5pp 10 of 18
Net margin Profitability 19.6% 6.9% 4 of 18
Stock pay as % of revenue Cash generation 0.9% 0.9% 5 of 8
Change in share count Balance sheet -5.3% -4.7% 7 of 16

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$11.6B
Institutions reporting
695
Shares held vs prior quarter
▲ 1.2%
Positions opened / closed
98 / 59

Top buyers and sellers, Q2 2026: 334 institutions bought and 271 sold ; the biggest buyer was Invesco Ltd (+603K shares) and the biggest seller Wellington Management Group LLP (−562K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $988M 5.5M 8.5% ▼ 0.2%
Vanguard Capital Management LLC $908M 5.1M 7.8% ▼ 1.3%
Invesco Ltd. $825M 4.6M 7.1% ▲ 15.0%
Vanguard Portfolio Management LLC $747M 4.2M 6.5% ▼ 1.7%
State Street Corp $667M 3.7M 5.8% ▲ 2.1%
Geode Capital Management, LLC $500M 2.8M 4.3% ▲ 2.8%
Dimensional Fund Advisors LP $428M 2.4M 3.7% ▲ 1.7%
Morgan Stanley $347M 1.9M 3.0% ▲ 0.5%
AQR Capital Management LLC $271M 1.5M 2.3% ▲ 26.6%
Nuveen, LLC $267M 1.5M 2.3% ▼ 0.1%
Arrowstreet Capital, Limited Partnership $257M 1.4M 2.2% ▲ 2.7%
Pzena Investment Management LLC $242M 1.4M 2.1% ▲ 32.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Globe Life's complete shareholder register. Values are as reported by the filers ; 4 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $82.9M 81 trades by 12 insiders · 0% under pre-set plans
Net ▼ $82.9M net selling
Insider Date Trade Shares Price Value
Majors Michael Clay EVP - Chief Strategy Officer October 23, 2026 Sell 14,377 $154.48 $2.2M
Hensley Robert Edward EVP & Chief Investment Officer September 22, 2026 Sell 6,656 $170.34 $1.1M
Hensley Robert Edward EVP & Chief Investment Officer September 22, 2026 Sell 3,344 $169.53 $566,912
Mitchell Robert Brian EVP, General Counsel and CRO August 7, 2026 Sell 1,017 $184.75 $187,892
Mitchell Robert Brian EVP, General Counsel and CRO August 7, 2026 Sell 10,529 $183.83 $1.9M
Mitchell Robert Brian EVP, General Counsel and CRO August 7, 2026 Sell 11,454 $182.77 $2.1M
Darden James Matthew Co-Chairman & CEO July 31, 2026 Sell 400 $183.36 $73,343
Darden James Matthew Co-Chairman & CEO July 31, 2026 Sell 49,600 $182.43 $9M
Kalmbach Thomas Peter EVP & CFO July 30, 2026 Sell 2,790 $181.81 $507,264
Kalmbach Thomas Peter EVP & CFO July 30, 2026 Sell 2,650 $181.23 $480,255
Kalmbach Thomas Peter EVP & CFO July 30, 2026 Sell 4,840 $180.08 $871,578
Kalmbach Thomas Peter EVP & CFO July 30, 2026 Sell 10,720 $179.30 $1.9M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 4 trades and filings

No trades in Globe Life disclosed in the last 12 months; 4 earlier trades on record.

  • Lisa C. McClain(R-MI 9):Sale (full), $1,001 - $15,000, traded July 10, 2025, filed August 13, 2025
  • Lisa C. McClain(R-MI 9):Purchase, $1,001 - $15,000, traded June 17, 2025, filed August 13, 2025
  • Lois Frankel(D-FL 22):Sale (full), $1,001 - $15,000, traded September 8, 2023, filed October 10, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 3, 2027 estimated from the company's past filing pattern, not announced

  • October 21, 2026
  • July 22, 2026
  • April 22, 2026
  • February 4, 2026
  • October 22, 2025
  • July 23, 2025

Recent SEC filings

Data status

When each part of this page on Globe Life was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Globe Life in brief

What does Globe Life do?
Globe Life is a US-listed company in the life & health insurance industry. Its financial year ends in December.
What is Globe Life's stock ticker?
Globe Life trades under the ticker GL on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Globe Life's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Globe Life reported revenue of $6.2B, 5.2% higher than a year earlier, according to its SEC filings.
What is Globe Life's free cash flow?
Globe Life's free-cash-flow margin is 19.9% of revenue over the trailing twelve months.
Who are Globe Life's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Invesco Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Globe Life buying back stock, and does it pay a dividend?
Globe Life spent $881M on share repurchases over the trailing twelve months, and its diluted share count fell 5.3% over the year.
What is Globe Life's market cap?
On November 2, 2026, Globe Life's market capitalisation was about $12.8B, with a price-to-earnings ratio of 10.6 and net debt of $2.7B. Market figures come from third-party market data and may be delayed.
Does Globe Life pay a dividend?
Yes: Globe Life paid $90.6M in dividends over the trailing twelve months, a dividend yield of 0.61% and a payout ratio of 7.5%.
Who are Globe Life's competitors?
In our Life & Health Insurance peer group, the companies closest to Globe Life are F&G Annuities & Life, Inc., Jackson Financial Inc., Manulife Financial Corp, Brighthouse Financial, Inc. and Genworth Financial Inc. The side-by-side comparison below sets their revenue, margins and growth against Globe Life's.
Are insiders buying or selling Globe Life stock?
Over the last 12 months, Globe Life's directors and officers reported 0 open-market purchases and 81 sales on Form 4. The insider trading page charts every trade.
When is Globe Life's next earnings date?
Around February 3, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Globe Life announces its own schedule.